Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Equities research analysts at Northcoast Research raised their Q4 2018 earnings per share (EPS) estimates for shares of Zimmer Biomet Holdings in a note issued to investors on Friday. Northcoast Research analyst D. Keiser now anticipates that the medical equipment provider will post earnings per share of $2.64 for the quarter, up from their previous forecast of $2.61.

Zimmer Biomet Holdings (NYSE:ZBH) last released its quarterly earnings results on Thursday, April 27th. The medical equipment provider reported $2.13 earnings per share for the quarter, beating the Zacks’ consensus estimate of $2.11 by $0.02. Zimmer Biomet Holdings had a return on equity of 16.80% and a net margin of 6.36%. The business had revenue of $1.98 billion during the quarter, compared to analyst estimates of $1.96 billion. During the same quarter last year, the company posted $2.00 EPS. Zimmer Biomet Holdings’s revenue for the quarter was up 3.8% on a year-over-year basis.

WARNING: This report was originally reported by American Banking News and is the property of of American Banking News. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.americanbankingnews.com/2017/07/10/q4-2018-eps-estimates-for-zimmer-biomet-holdings-inc-zbh-raised-by-analyst.html.

A number of other research analysts have also recently issued reports on the company. Needham & Company LLC boosted their target price on Zimmer Biomet Holdings from $151.00 to $153.00 and gave the company a “strong-buy” rating in a research note on Friday, April 28th. Oppenheimer Holdings, Inc. set a $132.00 target price on Zimmer Biomet Holdings and gave the company a “buy” rating in a research note on Friday, April 28th. Zacks Investment Research cut Zimmer Biomet Holdings from a “hold” rating to a “sell” rating in a research report on Tuesday, April 4th. Goldman Sachs Group, Inc. (The) began coverage on Zimmer Biomet Holdings in a research report on Tuesday, May 16th. They set a “sell” rating and a $92.00 price objective for the company. Finally, Royal Bank of Canada reaffirmed a “buy” rating and set a $133.00 price objective on shares of Zimmer Biomet Holdings in a research report on Tuesday, March 14th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $138.31.

Zimmer Biomet Holdings (ZBH) opened at 127.11 on Monday. The company has a 50 day moving average price of $123.43 and a 200-day moving average price of $117.75. The firm has a market cap of $25.63 billion, a price-to-earnings ratio of 52.03 and a beta of 1.21. Zimmer Biomet Holdings has a 52-week low of $95.63 and a 52-week high of $133.21.

The company also recently declared a quarterly dividend, which will be paid on Friday, July 28th. Stockholders of record on Friday, June 23rd will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.76%. The ex-dividend date of this dividend is Wednesday, June 21st. Zimmer Biomet Holdings’s payout ratio is 39.67%.

In other news, insider Sang Yi sold 17,731 shares of the stock in a transaction on Monday, June 12th. The stock was sold at an average price of $124.56, for a total value of $2,208,573.36. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider David C. Dvorak sold 87,331 shares of the stock in a transaction on Thursday, April 27th. The shares were sold at an average price of $116.47, for a total value of $10,171,441.57. Following the completion of the transaction, the insider now owns 381,886 shares of the company’s stock, valued at $44,478,262.42. The disclosure for this sale can be found here. Insiders sold a total of 111,262 shares of company stock valued at $13,103,927 over the last quarter. 1.07% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently made changes to their positions in the company. Cibc World Markets Corp raised its position in shares of Zimmer Biomet Holdings by 52.9% in the first quarter. Cibc World Markets Corp now owns 21,007 shares of the medical equipment provider’s stock valued at $2,565,000 after buying an additional 7,269 shares in the last quarter. Thrivent Financial for Lutherans raised its position in Zimmer Biomet Holdings by 6.7% in the fourth quarter. Thrivent Financial for Lutherans now owns 7,144 shares of the medical equipment provider’s stock valued at $737,000 after buying an additional 450 shares during the period. Auxier Asset Management raised its position in Zimmer Biomet Holdings by 3.3% in the fourth quarter. Auxier Asset Management now owns 86,514 shares of the medical equipment provider’s stock valued at $8,928,000 after buying an additional 2,750 shares during the period. DnB Asset Management AS raised its position in Zimmer Biomet Holdings by 16.2% in the first quarter. DnB Asset Management AS now owns 22,208 shares of the medical equipment provider’s stock valued at $2,712,000 after buying an additional 3,100 shares during the period. Finally, Israel Discount Bank of New York acquired a new position in Zimmer Biomet Holdings during the first quarter valued at $721,000. 84.34% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Holdings Company Profile

Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.

Earnings History and Estimates for Zimmer Biomet Holdings (NYSE:ZBH)

Receive News & Ratings for Zimmer Biomet Holdings Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet Holdings Inc. and related companies with MarketBeat.com's FREE daily email newsletter.